Rumors about a merger between AstraZeneca PLC and Bristol-Myers Squibb Company have cooled down, but both companies remain strong players in cancer and immune-mediated inflammatory diseases markets. Each company has distinct advantages and some weaknesses in their drug portfolios compared to the other. Investors are encouraged to evaluate the long-term potential of AstraZeneca versus Bristol-Myers Squibb independently, as both hold promising positions in their respective fields. The analysis aims to help investors decide which stock might be more attractive for long-term investment.
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
AstraZeneca retained a 'buy' rating from Citi despite mixed updates on its drug pipeline. Positive Phase III trial results for Tagrisso plus Orpathys in lung cancer showed significant survival benefits, with Citi estimating $500 million in peak sales...
AstraZeneca announced positive late-stage trial results for a two-drug combination treating a resistant form of lung cancer. The combo pairs Tagrisso, an established lung cancer pill, with Orpathys, a newer drug targeting the MET protein that causes ...
